1. National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00 PM – 9:30 PM San Francisco, California
Moderator Neil Love, MD
Faculty
Charles D Blanke, MD
David Cunningham, MD
Steven A Curley, MD
Eileen M O’Reilly, MD
Eric Van Cutsem, MD, PhD
Andrew X Zhu, MD, PhD 1 1

2. Case presented by Dr Moriarty
79 yo man with rectal bleeding
Early 2010: Resection of T3bN2 Grade II colon ca  opted for capecitabine in lieu of adjuvant FOLFOX
During last 8 weeks of chemotx, ↑CEA (from 3 10) and PET/CT = 4.8 cm hepatic met
Started on FOLFOX/bevacizumab to assess “chemosensitivity” prior to local treatment of isolated metastatic lesion

3. 3

4. Case presented by Dr Moriarty
79 yo man with rectal bleeding
Early 2010: Resection of T3bN2 Grade II colon ca  opted for capecitabine in lieu of adjuvant FOLFOX
During last 8 weeks of chemotx, ↑CEA (from 3 10) and PET/CT = 4.8 cm hepatic met
Started on FOLFOX/bevacizumab to assess “chemosensitivity” prior to local treatment of isolated metastatic lesion

5. 5

6. Case presented by Dr Moriarty
79 yo man with rectal bleeding
Early 2010: Resection of T3bN2 Grade II colon ca  opted for capecitabine in lieu of adjuvant FOLFOX
During last 8 weeks of chemotx, ↑CEA (from 3 10) and PET/CT = 4.8 cm hepatic met
Started on FOLFOX/bevacizumab to assess “chemosensitivity” prior to local treatment of isolated metastatic lesion

7. 7

8. Case presented by Dr Moriarty
79 yo man with rectal bleeding
Early 2010: Resection of T3bN2 Grade II colon ca  opted for capecitabine in lieu of adjuvant FOLFOX
During last 8 weeks of chemotx, ↑CEA (from 3 10) and PET/CT = 4.8 cm hepatic met
Started on FOLFOX/bevacizumab to assess “chemosensitivity” prior to local treatment of isolated metastatic lesion

9. Ongoing Phase II/III Trials: Liver Only CRC Metastases
Study
Phase
Target Accrual
Design
Study Endpoints
HEPATICA
III
500
(open)
Post-op XELOX +/ bevacizumab
3 yr DFS OS
NSABP C-11
670
(on hold)
Peri- versus Post-op:
mFOLFOX6 or FOLFIRI + bevacizumab
RFS
NHS: USTCU-EPOC
340
Peri-op FOLFOX +/- cetuximab
PFS
ORR
SIRFLOX
II/III
450
XELOX +/- yttrium-90 microspheres
NSABP FC-6 II 60
Unresectable: mFOLFOX7 + cetuximab
R0 resection rate
January 2011.

10. National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00 PM – 9:30 PM San Francisco, California
Moderator Neil Love, MD
Faculty
Charles D Blanke, MD
David Cunningham, MD
Steven A Curley, MD
Eileen M O’Reilly, MD
Eric Van Cutsem, MD, PhD
Andrew X Zhu, MD, PhD 10 10

11. Meta-Analysis of Studies with >100 Patients Who Underwent Liver Resections for CLM with >24 Months of Follow-Up ( ): Results
Postoperative mortality
0-4%
Most common postoperative fatal complications
Hepatic failure (23.8%)
Sepsis (15.5%)
Myocardial infarction (14.3%)
Postoperative blood transfusions
36% (64.3% in previous reports)
5-yr survival (range)
38% (16%-71%)
Taylor A et al. Proc ESMO 2010;Abstract 632P.

12. Case presented by Dr Moriarty
79 yo man with rectal bleeding
Early 2010: Resection of T3bN2 Grade II colon ca  opted for capecitabine in lieu of adjuvant FOLFOX
During last 8 weeks of chemotx, ↑CEA (from 3 10) and PET/CT = 4.8 cm hepatic met
Started on FOLFOX/bevacizumab to assess “chemosensitivity” prior to local treatment of isolated metastatic lesion